MEDICAL CANNABIS COMPANY

Transcription

1 MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: info@revivethera.com

2 Forward looking statements Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as may, will, should, expect, plan, anticipate, believe, intend, estimate, predict, potential, continue or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

3 Revive Therapeutics Unique medical cannabis company Novel products for the Over-the-counter, Medical Rx and Pharmaceutical markets Strategic collaboration with WeedMD for R&D, supply, and commercialization Experienced management team, scientific advisors, and strategic relationships

4 Global Medical Cannabis Opportunity $180 Billion total addressable market 1 North America Market size: ~ 4 mm kg Europe Market size: ~ 2 mm kg Asia Market size: Unknown Africa South America Market size: Market size: ~ 0.5 mm kg Australia Market size: ~ 2 mm kg ~ 0.2 mm kg 1 At Maturity, Source: Eight Capital, The Value Case for Investing in the Cannabis Sector. 2 Source: Grandview Research 2017, N Engl J Med 2013; 368:e30 May 30, 2013

5 Global Medical Cannabis Drivers Canada is a world leader More countries moving towards legalization in medical cannabis Demand for validated medical products Increasing acceptance of cannabis Significant for medical purposes research growth of cannabis for medical uses Rapidly aging population, healthcare costs, opioid risks

6 Medical Cannabis Potential ECS impacts various biological functions Cannabinoids shown to treat +100 diseases CB1 Receptors General well-being Prion/Mad Cow disease Irritable bowel OCD Acne Metabolic syndrome Kidney disease Osteoporosis Found in the brain, and also in the ADD/ADHD Migraine Liver disease Parkinson s reproductive system of both males and Addiction Mood disorders Nausea Heart disease females. CB1 Receptors appear to be AIDs Motion sickness Neuropathic pain Huntington s responsible for both the anti-convulsive ALS Multiple sclerosis Stress Inflammation and euphoric effects of cannabis. Alzheimer s Skin conditions Stroke/TBI Cancer Anorexia Sleep disorders PTSD Colitis/Crohn s CB2 Receptors Antibiotic resistance Spinal cord injury Rheumatism Many more Anxiety Diabetes Schizophrenia Found predominantly in the immune Atherosclerosis Endocrine disorders Sickle cell anemia system. CB2 Receptors appear to be Arthritis Epilepsy/seizure Asthma responsible for several therapeutic effects Depression Fibromyalgia Autism of cannabis including the anti- Obesity Glaucoma Bipolar inflammatory responses. ECS = Human Endocannabinoid system

7 Strategic Innovation and R&D Novel Dosages, Scientific Evidence Approach for Growth Medical Affairs Patient Education and Care Business Development Collaborations, JVs, Acquisitions Clinical Studies Evidence-based, Data generation Commercialization Export Markets, Supply, Branding

8 Advancing medical cannabis products Innovation and R&D of effective products Commercialization New Product Development Sell OTC and Medical Rx direct from LPs & Retail pharmacies. Unmet Medical Needs R&D to validate novel products Licensing License patents from academia & industry. IP in cannabinoid delivery and liver diseases. Focus on pain, inflammation, and liver offering untapped multi-billion market opportunities. in unique dosage forms with collaborators. Patent Portfolio: 3 issued U.S. Patents and 2 patent applications filed with USPTO

9 Strategic Collaboration Research and Development of Novel & High Value Products Commercialization of OTC & Medical Rx Products WeedMD (TSXV: WMD) to merge with HIKU (CSE: HIKU) Leverage Core Strengths in Supply, Growing and Extraction Access to Direct and Retail Distribution

10 Strategic Product Approach Focusing on Three Product Growth Opportunities Pharmaceuticals Medical Rx Over-the-Counter

11 OTC Products Targeting Chronic Pain and Dermatology 1 in 5 Canadians 11 million CBD Chewing Gum PAIN suffer from chronic pain Canadians suffer from musculoskeletal Patented controlled-release every year conditions CBD chewing gum PSORIASIS 1 million Canadians diagnosed with Estimated up to 17% of Canadians will CBD Topical Cream Patented microencapsulated psoriasis have eczema

12 Medical Rx Products Developing Unique and High Value Prescription-based Products Global Anti- At least PSORIASIS inflammatory market to reach 100 million people affected with CBD Topical Cream $106 billion by 2020 psoriasis worldwide Patented Delivery Technology PAIN Global pain market to reach $83 billion In 2016, 385 million cases of neuropathic CBD Topical Cream by pain worldwide Patented Delivery Technology Global wound 387mm with CBD Topical Hydrogel WOUND CARE care market to diabetes globally, reach $35Bn ~3mm diabetic Patented Delivery Technology by 2022 ulcers annually

13 Pharmaceutical Strategy Rare liver & inflammatory skin diseases Granted ODD approval for CBD in Autoimmune Hepatitis Cannabinoid patents in liver and drug delivery R&D for scientific and clinical validation Pharma partnering potential Pharma Cannabis Leader $3.5bn market cap

14 Go Forward Strategy Focus on Growth SALES INNOVATE R&D PARTNERS BIZ DEV Achieve near-term Develop & Studies to expand Expand license Acquisitions, sales of OTC products commercialize unique IP & support producer & dealer collaborations, medical Rx products product claims relationship international markets Innovation, differentiation, high value, validation to accelerate growth

15 Revive Team Management Team and Advisors Board of Directors Craig Leon Fabio Chianelli Craig Leon Fabio Chianelli Chairman and CEO President and Director Chairman and CEO President and Director Titan Medical Titan Medical Carmelo Marrelli Dr. Bev Incledon William Jackson Carlo Sansalone Chief Financial Officer VP, Research and Development Director Director CFO to TSX listed firms Highland Therapeutics, Exec VP, R&D Atwill Medical Solutions Sanscon Dr. Arun Sanyal Scientific Advisor Prof Gastroenterology, Hepatology, Nutrition at VCU

16 Key Financial Information Ticker Symbols Share Price 52 week High/Low Capital Structure Market Cap Cash and Cash Equivalents RVV (TSX Venture) RVVTF (OTCQB) 31R (Borse Frankfurt) CAD $0.205 (June 26, 2018) CAD $0.51 / $ ,159,657 common shares (61,627,808 fully-diluted) CAD ~ $12,000,000 CAD $1,287,202 (as of March 31, 2018) Stock Options: 3,468,151 stock options $0.60; $0.66; $0.30; $0.28; $0.20; $0.335; $0.205)